One of the biggest drugs of the year, Abbvie’s Jak inhibitor upadacitinib, could get the nod in August.
The company hails a partial clinical trial win as the way in to a new use for Hetlioz, but the stock markets are less convinced.
A two-for-one holiday sale is coming for Hetlioz and tradipitant, and Evofem hopes to confirm its contraceptive gel's effectiveness.